Table 1.
Compound | Dose (100 ng/mL) | Cell Viability (% of Control) | NO Level | IC50 (μg/mL) |
---|---|---|---|---|
control | (−) | 94.5 ± 2.8 | 0.7 ± 0.4 | – |
LPS | (+) | 101.7 ± 0.5 | 19.7 ± 0.2 ### | – |
1 | 1.25 | 97.7 ± 5.1 | 19.1 ± 1.0 | |
2.5 | 94.7 ± 2.9 | 18.3 ± 0.5 | ||
5 | 89.8 ± 4.8 | 12.3 ± 0.2 ** | 8.5 ± 0.3 | |
10 | 86.9 ± 2.7 | 9.1 ± 0.1 *** | ||
20 | 81.3 ± 1.7 | 6.5 ± 0.3 *** | ||
2 | 1.25 | 85.3 ± 1.9 | 20.6 ± 0.1 | |
2.5 | 84.3 ± 2.5 | 20.0 ± 0.5 | ||
5 | 82.7 ± 1.7 | 17.0 ± 0.8 * | 9.6 ± 0.5 | |
10 | 80.6 ± 5.4 | 9.4 ± 0.7 *** | ||
20 | 64.5 ± 3.9 | (−) |
The data were presented as mean ± S.D; ###, compared with sample of control group; *, p < 0.05, **, p < 0.01, and ***, p < 0.001 were compared with LPS-alone group; –, not detectable; (−), no LPS adds to RAW 264.7 cells; (+), LPS adds to RAW 264.7 cells.